CD274 and neoplasm: Specific radiomic features associated with PD-L1 expression levels can aid in the precise selection of patients suitable for neoadjuvant immunotherapy, offering new posttreatment assessment methods by quantifying tumor shrinkage and pathologic response, thereby optimizing subsequent treatment plans (53).